[Clinical analysis of HLA-DR-negative non-M3 AML].
The type of leukemia was defined as HLA-DR(-) non-M3-AML, when HLA antigens were detected by flow cytometry at an incidence of < 20% of the blast population excluding M3-AML. Out of 109 patients with de novo acute myeloid leukemia, 8 patients had HLA-DR(-) non-AML-M3. According to the French-American-British criteria, 7 patients could be subdivided into 3 patients with M1, 4 patients with M2 and 1 patient with M4. The morphological features of bone marrow aspiration demonstrated no dysplasia and peroxidase stain positivity was noted in over 86% of the blast cells in all patients, the blast cells with fine granularity in 7 patients. The cytogenetic analysis revealed a normal karyotype. There was no expression marker of the blast antigens except CD13, CD14, CD33, CD34 and CD56. All of 7 patients who underwent induction therapy attained complete remission. Overall survival and disease-free survival showed no significant differences between the HLA-DR(-) non- M3-AML group and the HLA-DR(+) AML group.
Mori
Hiraku
H
Division of Hematology, Internal Medicine, Showa University Fujigaoka Hospital.
Sakai
Hirotaka
H
Sanada
Masashi
M
Shimamoto
Kenji
K
Sasaki
Satoko
S
Azuma
Remi
R
Higuchi
Takakazu
T
Harada
Hiroshi
H
Niikura
Haruo
H
Omine
Mitsuhiro
M
Fujita
Kazuhiro
K
Takahashi
Naoki
N
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000145:classification / Q000188:drug therapy / Q000276:immunology* / Q000401:mortality; D015473:Leukemia, Promyelocytic, Acute / Q000276:immunology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D006684:HLA-DR Antigens